The earnings call highlighted strong revenue and earnings growth, driven by robust performance in key segments like office and surgical, and myopia management. However, challenges such as fertility market softness, reduced market growth assumptions, and tariff impacts were also noted. While the highlights are significant, the lowlights point to underlying market challenges.

Company Guidance -

Q3 2025

During the Q2 2025 earnings call for The Cooper Companies, Al White, the President and CEO announced a consolidated organic revenue growth of 7%, with total revenues reaching $1,002 million, a 6% increase year-over-year. CooperVision's revenues were $670 million, up 5% or 7% organically, while CooperSurgical's revenues were $333 million, an 8% increase. The company reported a 14% increase in non-GAAP earnings, with earnings per share at $0.96. The revenue guidance for fiscal 2025 was adjusted to a range of $4,110 million to $4,150 million, reflecting a 5.5% to 6.5% increase or 5% to 6% organically. Al White emphasized the strong performance of daily silicone hydrogel lenses, particularly MyDay, which grew by 10%, and the promising growth of the Myopia management portfolio, which rose by 19%, with MiSight up 35%. The effective tax rate was 14.6%, and free cash flow was $18 million, with capital expenditures of $78 million. The company also updated its non-GAAP EPS guidance to a range of $4.05 to $4.11, indicating a 10% to 11.5% growth.

Strong Revenue Growth

Consolidated revenues were $1,002,000,000, up 6% year over year or up 7% organically. CooperVision revenues were $670,000,000, up 5% or 7% organically, and CooperSurgical revenues were $333,000,000, up 8% or 7% organically.

Non-GAAP Earnings Increase

Non-GAAP earnings were $0.96, up 14% year over year, driven by operational improvements and OpEx leverage.

Myopia Management Growth

Myopia management portfolio grew 19% with MiSight up 35%, supported by a new pricing model and increased fitting activity.

Office and Surgical Segment Performance

Office and Surgical sales were $206,000,000, up 13% or 10% organically, driven by minimally invasive gynecological surgical devices and labor and delivery products.

PARAGARD Growth

PARAGARD grew 18% this quarter, driven by channel fill before a price increase and continued interest in the new single hand inserter.

Cooper Co (COO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

COO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 27, 2025	2025 (Q3)	1.06 / -	0.96	―	―	―
May 29, 2025	2025 (Q2)	0.93 / 0.96	0.85	12.94% (+0.11)
Mar 06, 2025	2025 (Q1)	0.91 / 0.92	0.85	8.24% (+0.07)
Dec 05, 2024	2024 (Q4)	1.00 / 1.04	0.868	19.82% (+0.17)
Aug 28, 2024	2024 (Q3)	0.91 / 0.96	0.838	14.56% (+0.12)
May 30, 2024	2024 (Q2)	0.83 / 0.85	0.77	10.39% (+0.08)
Feb 29, 2024	2024 (Q1)	0.78 / 0.85	0.725	17.24% (+0.13)	―
Dec 07, 2023	2023 (Q4)	0.87 / 0.87	0.688	26.16% (+0.18)	―
Aug 30, 2023	2023 (Q3)	0.84 / 0.84	0.798	5.01% (+0.04)	―
Jun 01, 2023	2023 (Q2)	0.76 / 0.77	0.81	-4.94% (-0.04)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

COO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 29, 2025	$79.96	$68.28	-14.61%
Mar 06, 2025	$90.98	$85.00	-6.57%
Dec 05, 2024	$103.23	$98.70	-4.39%
Aug 28, 2024	$94.54	$105.73	+11.84%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.